Anthera Pharmaceuticals, Inc. (ANTH)

Market Cap	26.00
Revenue (ttm)	n/a
Net Income (ttm)	-24.93M
Shares Out	26.18M
EPS (ttm)	-1.76
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	187
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	n/a
Beta	-129.62
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Anthera Pharmaceuticals

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 21
• Stock Exchange: OTCMKTS
• Ticker Symbol: ANTH